

## **Product datasheet for TL514012**

## Troduct datasfieet for TEST4012

Fzd5 Mouse shRNA Plasmid (Locus ID 14367)

## Product data:

**Product Type:** shRNA Plasmids

**Product Name:** Fzd5 Mouse shRNA Plasmid (Locus ID 14367)

**Locus ID:** 14367

**Synonyms:** 5330434N09Rik; Al427138; Fz-5; Fz5; mFz5

**Vector:** pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** Fzd5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 14367).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: <u>BC117723</u>, <u>NM 001042659</u>, <u>NM 022721</u>, <u>NM 022721.1</u>, <u>NM 022721.2</u>, <u>NM 022721.3</u>,

NM 001042659.1

UniProt ID: 09EOD0

Summary: Receptor for Wnt proteins (PubMed:11092808, PubMed:18230341). Can activate WNT2,

WNT10B, WNT5A, but not WNT2B or WNT4 (in vitro); the in vivo situation may be different since not all of these are known to be coexpressed (PubMed:11092808). In neurons, activation of WNT7A promotes formation of synapses (By similarity). Functions in the canonical Wnt/beta-catenin signaling pathway (PubMed:18230341). The canonical Wnt/beta-catenin signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3

kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes

(PubMed:18230341). A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues (Probable). Plays a role in yolk sac angiogenesis and in placental vascularization (PubMed:11092808).[UniProtKB/Swiss-Prot


Function]



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="mailto:custom shRNA service">custom shRNA service</a>.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).